Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

11.76
Delayed Data
As of Mar 30
 -0.02 / -0.17%
Today’s Change
7.09
Today|||52-Week Range
12.24
+41.69%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$519.4M

Company Description

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company's psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Contact Information

Supernus Pharmaceuticals, Inc.
1550 East Gude Drive
Rockville Maryland 20850
P:(301) 838-2500
Investor Relations:
(301) 838-2522

Employees

Shareholders

Individual stakeholders45.24%
Other institutional35.15%
Mutual fund holders21.65%

Top Executives

Jack A. KhattarPresident, CEO, Director & Secretary
Gregory S. PatrickCFO, Vice President & Head-Investor Relations
Padmanabh P. BhattChief Scientific Officer & Senior Vice President
Stefan K. F. SchwabeChief Medical Officer, EVP-Research & Development
Jones Woody BryanVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account